Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

1629-P: Association between Dyslipidemia and Myosteatosis Evaluated by Abdominal Computed Tomography

View through CrossRef
Introduction: The association between dyslipidemia and myosteatosis measured using muscular quality map in abdominal computed tomography(CT) was analyzed in a large population. Methods: Abdominal CT of 20,210 subjects were evaluated to measure total abdominal muscle area (TAMA) at L3 level. TAMA was segmented into intramuscular adipose tissue and skeletal muscle area (SMA), which was further classified into normal attenuation muscle area (NAMA: good quality muscle) and low attenuation muscle area (LAMA: poor quality muscle). Myosteatosis indices used were SMA/body mass index(BMI), NAMA/BMI, NAMA/TAMA, and LAMA/BMI. Dyslipidemia was defined as high-density lipoprotein cholesterol(HDL-C) less than 40mg/dL in men and 50mg/dL in women, low-density lipoprotein cholesterol(LDL-C) greater than 160mg/dL, or triglycerides(TG) greater than 150mg/dL. Results: According to multiple logistic regression analyses, the odds ratios (ORs) of dyslipidemia according to HDL and LDL definitions showed a decreasing trend with increasing quartiles for SMA/BMI, NAMA/BMI, and NAMA/TAMA (P for trend < 0.001 for all). The adjusted ORs (95% confidence intervals[CIs]) for dyslipidemia in Q2, Q3, and Q4 for NAMA/TAMA compared with Q1 were 0.87 (0.79-0.96), 0.76 (0.69-0.85) and 0.55 (0.49-0.61) according to the HDL definition and 0.93 (0.83-1.05), 0.95 (0.84-1.07), and 0.69 (0.60-0.79) according to the LDL definition. Conversely, the ORs of dyslipidemia according to HDL and LDL showed an increasing trend according to increasing LAMA/BMI quartiles (P for trend < 0.001 for all). Dyslipidemia according to TG did not show a significant association after adjustment. Conclusion: Dyslipidemia according to HDL-C and LDL-C definitions is associated with myosteatosis, positively with bad quality (unhealthy) muscle and negatively with good quality (healthy) muscle. Muscle quality may be an important risk factor for dyslipidemia and ensuing cardiometabolic diseases. Disclosure H.Kim: None. H.Jung: None. Y.Cho: None. W.Lee: None. C.Jung: None.
Title: 1629-P: Association between Dyslipidemia and Myosteatosis Evaluated by Abdominal Computed Tomography
Description:
Introduction: The association between dyslipidemia and myosteatosis measured using muscular quality map in abdominal computed tomography(CT) was analyzed in a large population.
Methods: Abdominal CT of 20,210 subjects were evaluated to measure total abdominal muscle area (TAMA) at L3 level.
TAMA was segmented into intramuscular adipose tissue and skeletal muscle area (SMA), which was further classified into normal attenuation muscle area (NAMA: good quality muscle) and low attenuation muscle area (LAMA: poor quality muscle).
Myosteatosis indices used were SMA/body mass index(BMI), NAMA/BMI, NAMA/TAMA, and LAMA/BMI.
Dyslipidemia was defined as high-density lipoprotein cholesterol(HDL-C) less than 40mg/dL in men and 50mg/dL in women, low-density lipoprotein cholesterol(LDL-C) greater than 160mg/dL, or triglycerides(TG) greater than 150mg/dL.
Results: According to multiple logistic regression analyses, the odds ratios (ORs) of dyslipidemia according to HDL and LDL definitions showed a decreasing trend with increasing quartiles for SMA/BMI, NAMA/BMI, and NAMA/TAMA (P for trend < 0.
001 for all).
The adjusted ORs (95% confidence intervals[CIs]) for dyslipidemia in Q2, Q3, and Q4 for NAMA/TAMA compared with Q1 were 0.
87 (0.
79-0.
96), 0.
76 (0.
69-0.
85) and 0.
55 (0.
49-0.
61) according to the HDL definition and 0.
93 (0.
83-1.
05), 0.
95 (0.
84-1.
07), and 0.
69 (0.
60-0.
79) according to the LDL definition.
Conversely, the ORs of dyslipidemia according to HDL and LDL showed an increasing trend according to increasing LAMA/BMI quartiles (P for trend < 0.
001 for all).
Dyslipidemia according to TG did not show a significant association after adjustment.
Conclusion: Dyslipidemia according to HDL-C and LDL-C definitions is associated with myosteatosis, positively with bad quality (unhealthy) muscle and negatively with good quality (healthy) muscle.
Muscle quality may be an important risk factor for dyslipidemia and ensuing cardiometabolic diseases.
Disclosure H.
Kim: None.
H.
Jung: None.
Y.
Cho: None.
W.
Lee: None.
C.
Jung: None.

Related Results

1699-P: Association between Insulin Resistance and Myosteatosis Measured by Abdominal Computed Tomography
1699-P: Association between Insulin Resistance and Myosteatosis Measured by Abdominal Computed Tomography
Background: Ectopic fat deposition in skeletal muscle, termed myosteatosis, is a key factor in developing insulin resistance. We aimed to evaluate the association between insulin r...
Renal Ewing Sarcoma: A Case Report and Literature Review
Renal Ewing Sarcoma: A Case Report and Literature Review
Abstract Introduction Primary renal Ewing sarcoma is an extremely rare and aggressive tumor, representing less than 1% of all renal tumors. This case report contributes valuable in...
Association of Lipid Profile Abnormalities with NAFLD Severity in Patients with Metabolic Syndrome
Association of Lipid Profile Abnormalities with NAFLD Severity in Patients with Metabolic Syndrome
Background: Nonalcoholic fatty liver disease (NAFLD) is becoming a significant global health issue, and it is frequently associated with metabolic conditions, including hypertensio...
Avaliação da dor abdominal aguda em adultos
Avaliação da dor abdominal aguda em adultos
Introdução: A maioria dos pacientes com dor abdominal tem uma etiologia benigna e/ou autolimitada. O objetivo inicial da avaliação é identificar os pacientes que têm uma etiologia ...
Dyslipidemia and its predictors among adult workers in eastern Ethiopia: An institution-based cross-sectional study
Dyslipidemia and its predictors among adult workers in eastern Ethiopia: An institution-based cross-sectional study
Introduction Dyslipidemia is a modifiable major risk factor for coronary heart disease. Although, the prevalence of dyslipidemia in high-income countries has been well documented, ...

Back to Top